Weiss Multi-Strategy Advisers’s BioXcel Therapeutics BTAI Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,873	Closed	-$609K	–	667
2021 Q4	$609K	Sell	1,873 -7	-0.4%	-$3K	0.01%	532
2021 Q3	$913K	Buy	1,880 +106	+6%	+$46.6K	0.02%	501
2021 Q2	$825K	Buy	1,774 +392	+28%	+$214K	0.02%	513
2021 Q1	$954K	Buy	1,382 +203	+17%	+$163K	0.02%	489
2020 Q4	$871K	Buy	1,179 +233	+25%	+$181K	0.02%	505
2020 Q3	$657K	Buy	+946	New	+$710K	0.02%	456

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Weiss Multi-Strategy Advisers's BTAI Position: Q1 2022 in Review

Weiss Multi-Strategy Advisers sold out of BioXcel Therapeutics (BTAI) in Q1 2022, closing a stake of 1,873 shares — an estimated $609K sold.

Weiss Multi-Strategy Advisers first reported a position in BTAI in Q3 2020 and held it in 6 quarters. The position peaked at $954K in Q1 2021. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2022.

Weiss Multi-Strategy Advisers reported no remaining BioXcel Therapeutics position as of Q1 2022 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 1,873 BioXcel Therapeutics shares in Q1 2022, an estimated $609K.
Weiss Multi-Strategy Advisers first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 6 quarters.
Weiss Multi-Strategy Advisers's BioXcel Therapeutics position peaked at $954K in Q1 2021.
96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2022.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2022, filed 16 May 2022.